Family Routines Enhancing Adolescent Diabetes by Optimizing Management (FREADOM)
Primary Purpose
Type 1 Diabetes
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sleep Extension
Routine
Sponsored by
About this trial
This is an interventional treatment trial for Type 1 Diabetes focused on measuring Youth, Diabetes Management, Sleep
Eligibility Criteria
Inclusion Criteria:
- Type 1 diabetes
Exclusion Criteria:
- neurological, developmental, or psychiatric condition that in the opinion of the PI would significantly interfere with sleep or participation
- not hospitalized within the previous month prior to enrollment
Sites / Locations
- Pediatric Endocrinology ClinicRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Sleep Extension
Routine
Arm Description
All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
All youth in this condition are asked to follow the routine that their clinical team has established.
Outcomes
Primary Outcome Measures
HbA1c
A measure of glucose control
Secondary Outcome Measures
Glucose Levels via continuous glucose monitor
Glucose levels will be measured at regular intervals using a subcutaneous continuous glucose monitor
Sleep Duration
Sleep duration will be measured using a combination of wrist actigraphy and polysomnography data.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02974309
Brief Title
Family Routines Enhancing Adolescent Diabetes by Optimizing Management
Acronym
FREADOM
Official Title
Extending Sleep to Improve Glycemic Control in Pediatric Type 1 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 15, 2017 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Arizona
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A three month randomized study to examine the potential benefits of sleep extension in tandem with clinical trial on diabetes management in youth with type 1 diabetes.
Detailed Description
Type 1 Diabetes (T1DM) is one of the most common chronic medical conditions that occur in children. More than two-thirds of these young patients struggle to maintain optimal glycemic control. On a seemingly unrelated front, insufficient sleep has become a public health crisis as less than 30% of youth achieve the recommended number of hours on school nights. Prior research has supported that sleep disturbances contribute to elevated glucose levels and have a significant impact on memory, attention, and planning. These skills are essential to effective diabetes management. Despite the link between sleep and diabetes, no research has examined the benefits of an intervention to help these youth achieve a healthy sleep duration. To that end, our primary objective is to determine the effect of sleep extension on glycemic control and psychosocial functioning. Our secondary objective is to determine mediators and moderators of effect. The central hypothesis is that an increase in sleep duration will lower glucose levels and improve behavioral ratings (internalizing, externalizing, and classroom behaviors). Our primary study aims are to (1) Test if lengthening sleep improves glycemic control and psychosocial function in youth with T1DM; (2) Assess putative mechanisms for the effects of sleep extension on glucose and psychosocial function; and (3) Examine the possible moderating effect of pre-existing sleep parameters and sociodemographic variables that modify the impact of sleep extension. A secondary aim is exploratory to examine additional pre-selected mediators and moderators. In the proposed randomized study, up to 175 youth with T1DM will be assigned to a Sleep Extension or a supportive routines condition. The Sleep Extension lengthens youth's time in bed to allow for a healthy sleep duration on a consistent basis, whereas the supportive routines condition reinforces daytime and nighttime activities. We will test the impact of sleep extension on key indices of glycemic control (average glucose levels and % time hyperglycemia using continuous glucose monitors and HbA1C) as well as putative mechanisms of effect (e.g., heart rate variability and salivary cortisol levels) and participant characteristics that might mitigate the benefits of sleep extension (e.g., sleep-disordered breathing, adherence, and SES). Once our aims are achieved and a causal link is established, the proposed Sleep Extension intervention will advance knowledge about the role of sleep in diabetes management and provide a beneficial intervention to help youth with T1DM.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
Youth, Diabetes Management, Sleep
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
175 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sleep Extension
Arm Type
Experimental
Arm Description
All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
Arm Title
Routine
Arm Type
Sham Comparator
Arm Description
All youth in this condition are asked to follow the routine that their clinical team has established.
Intervention Type
Behavioral
Intervention Name(s)
Sleep Extension
Intervention Description
All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
Intervention Type
Behavioral
Intervention Name(s)
Routine
Intervention Description
All youth in this condition are asked to follow the routines set by their clinical care team.
Primary Outcome Measure Information:
Title
HbA1c
Description
A measure of glucose control
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Glucose Levels via continuous glucose monitor
Description
Glucose levels will be measured at regular intervals using a subcutaneous continuous glucose monitor
Time Frame
1 and 3 months
Title
Sleep Duration
Description
Sleep duration will be measured using a combination of wrist actigraphy and polysomnography data.
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
Diabetes Self-Management
Description
Diabetes self-management and care activities will be assessed using the Diabetes Self-Management Profile for Flexible Regimes, Self- and Parent-proxy reports
Time Frame
1 and 3 months
Title
Adherence to Diabetes Management
Description
Adherence to diabetes management will be measured using the average daily manual glucose measurements from a personal glucometer (i.e. finger sticks)
Time Frame
1 and 3 months
Title
Polysomnographic Sleep Architecture
Description
Sleep architecture will be measured as percent time spent sleeping in the different stages of sleep (NREM 1, 2, 3, REM) using an in-home polysomnography system.
Time Frame
1 and 3 months
Title
Quality of Life
Description
Quality of Life will be measured using an aggregate of the Pediatric Quality of Life Inventory (PedsQL) Core 4.0 and Diabetes 3.2 modules.
Time Frame
1 and 3 months
Title
Cortisol
Description
Morning and evening Cortisol levels will be measured using a saliva collection device
Time Frame
1 and 3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 1 diabetes
Exclusion Criteria:
neurological, developmental, or psychiatric condition that in the opinion of the PI would significantly interfere with sleep or participation
not hospitalized within the previous month prior to enrollment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michelle M Perfect, PhD
Phone
5206261128
Email
mperfect@email.arizona.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle M Perfect, PhD
Organizational Affiliation
UA College of Education
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pediatric Endocrinology Clinic
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85719
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle M Perfect, Ph.D.
First Name & Middle Initial & Last Name & Degree
Mark Wheeler, MD
First Name & Middle Initial & Last Name & Degree
Cyndi Chin, MD
First Name & Middle Initial & Last Name & Degree
Stuart Quan, MD
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Upon request.
Learn more about this trial
Family Routines Enhancing Adolescent Diabetes by Optimizing Management
We'll reach out to this number within 24 hrs